Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study
Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3094-3103
DOI: 10.1111/dom.16316 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.03.2025. Verfasst von Emma Simonsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Diabetes Mellitus, Type 2, Optic Neuropathy, Ischemic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danmarks Frie Forskningsfond.
Abstract (Originalsprache)
Aims
To investigate the putative association between semaglutide and non‐arteritic anterior ischaemic optic neuropathy (NAION). Materials and Methods Data from national health registries in Denmark (2018–2024) and Norway (2018–2022) were used to compare NAION risk in individuals with type 2 diabetes initiating semaglutide versus sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2is). A supplementary self‐controlled analysis examined NAION risk among all semaglutide users. National estimates were pooled using a fixed‐effects model.
Results
We identified 44 517 users of semaglutide for the management of type 2 diabetes in Denmark and 16 860 in Norway, with a total of 32 NAION events observed. The unadjusted incidence rate of NAION was 2.19/10 000 person‐years among Danish semaglutide initiators, compared to 1.18 among SGLT‐2i initiators. In Norway, the corresponding rates were 2.90 and 0.92, respectively. After adjustment, the pooled hazard ratio (HR) was 2.81 (95% confidence interval [CI] 1.67–4.75), and the incidence rate difference (IRD) was +1.41 (95% CI +0.53 to +2.29) per 10 000 person‐years. Estimates were consistent across both countries but higher and less precise in Norway (HR 7.25; 95% CI 2.34–22.4) compared to Denmark (HR 2.17; 95% CI 1.20–3.92). Results remained consistent across sensitivity and supplementary analyses, with a stronger association observed in a post hoc per‐protocol analysis (HR 6.35; 95% CI 2.88–14.0). In the supplementary self‐controlled study, symmetry ratios (SRs) for NAION were 1.14 (95% CI 0.55–2.36) in Denmark and 2.67 (95% CI 0.91–8.99) in Norway.
Conclusions
The use of semaglutide for managing type 2 diabetes is associated with an increased risk of NAION compared with the use of SGLT‐2is. However, the absolute risk remains low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Endocrinology, Odense University Hospital, Odense, Denmark.
- Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Department of Ophthalmology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Emma Simonsen, Lars Christian Lund, Martin Thomsen Ernst, Vidar Hjellvik, Steffen Hamann, Øystein Kalsnes Jørstad, Hanne Løvdal Gulseth, Øystein Karlstad, Anton Pottegård
Förderung
- Danmarks Frie Forskningsfond
Zitieren
APA
Simonsen, E., Lund, L. C., Ernst, M. T., Hjellvik, V., Hegedüs, L., Hamann, S., Jørstad, Ø. K., Gulseth, H. L., Karlstad, Ø., & Pottegård, A. (2025). Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study. Diabetes, Obesity and Metabolism, 27(6), 3094-3103. https://doi.org/10.1111/dom.16316
Vancouver
Simonsen E, Lund LC, Ernst MT, Hjellvik V, Hegedüs L, Hamann S, et al. Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study. Diabetes, Obesity and Metabolism. 2025;27(6):3094-3103. doi:10.1111/dom.16316
BibTeX
@article{Simonsen2025,
author = {Simonsen, Emma and Lund, Lars Christian and Ernst, Martin Thomsen and Hjellvik, Vidar and Hegedüs, Laszlo and Hamann, Steffen and Jørstad, Øystein Kalsnes and Gulseth, Hanne Løvdal and Karlstad, Øystein and Pottegård, Anton},
title = {Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {6},
pages = {3094--3103},
doi = {10.1111/dom.16316}
}
EUVIMED